{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:33:36Z","timestamp":1782538416651,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.humpath.2021.06.003","type":"journal-article","created":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T00:36:52Z","timestamp":1624063012000},"page":"76-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["TP53 variant allele frequency correlates with the chemotherapy response score in ovarian\/fallopian tube\/peritoneal high-grade serous carcinoma"],"prefix":"10.1016","volume":"115","author":[{"given":"Barrett C.","family":"Lawson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Euscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4816-507X","authenticated-orcid":false,"given":"Preetha","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anais","family":"Malpica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2021.06.003_bib1","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2021.06.003_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080023","article-title":"Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations","volume":"8","author":"Birkbak","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.humpath.2021.06.003_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2021.06.003_bib4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutation load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2021.06.003_bib5","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25544","article-title":"High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia","volume":"94","author":"Patel","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.humpath.2021.06.003_bib6","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1182\/blood-2018-01-828467","article-title":"High NPM1-mutatant allele burden at diagnosis predicts unfavorable outcomes in de novo AML","volume":"131","author":"Patel","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2021.06.003_bib7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","article-title":"Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes","volume":"4","author":"Montalban-Bravo","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2021.06.003_bib8","article-title":"Exploratory analysis of TP53 mutations in circulating tumor DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study","volume":"13","author":"Parkinson","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.humpath.2021.06.003_bib9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/1541-7786.MCR-18-0034","article-title":"Biomarkers assessment of HR deficiency, tumor BRCA1\/2 mutations, and CCNE1 copy number in ovarian cancer: associations with clinical outcome following platinum monotherapy","volume":"16","author":"Stronach","year":"2018","journal-title":"Mol Canc Res"},{"key":"10.1016\/j.humpath.2021.06.003_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-018-0590-x","article-title":"Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors","volume":"10","author":"Yang","year":"2018","journal-title":"Genome Med"},{"key":"10.1016\/j.humpath.2021.06.003_bib11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/jnci\/djs177","article-title":"A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy","volume":"104","author":"Kang","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2021.06.003_bib12","first-page":"9571","article-title":"Digital immune-related gene expression signatures in high-grade serous ovarian carcinoma: developing prediction models for platinum response","volume":"11","author":"Mairinger","year":"2019","journal-title":"Canc Manag Res"},{"key":"10.1016\/j.humpath.2021.06.003_bib13","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2021.06.003_bib14","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3389\/fonc.2019.00778","article-title":"Pathological chemotherapy response score in patients affected by high grade serous ovarian carcinoma: the prognostic role of omental and ovarian residual disease","volume":"9","author":"Santoro","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.humpath.2021.06.003_bib15","series-title":"Protocol for the examination of specimens from patients with primary tumors of the ovary, fallopian tube or peritoneum. Version: ovary fallopian 1.1.1.0","year":"2020"},{"key":"10.1016\/j.humpath.2021.06.003_bib16","series-title":"Dataset for ovary, fallopian tube and primary peritoneal carcinomas. Version 1.0 Ovary, Fallopian Tube, Peritoneal Carcinoma","author":"International Collaboration on cancer reporting","year":"2015"},{"key":"10.1016\/j.humpath.2021.06.003_bib17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ygyno.2019.04.679","article-title":"Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data","volume":"154","author":"Cohen","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2021.06.003_bib18","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000513","article-title":"Assessment of a chemotherapy response score (CRS) system for tubo-ovarian high-grade serous carcinoma (HGSC)","volume":"38","author":"Ditzel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.humpath.2021.06.003_bib19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/PAS.0000000000001391","article-title":"A 3-tier chemotherapy response score for ovarian\/fallopian tube\/peritoneal high-grade serous carcinoma: is it clinically relevant?","volume":"44","author":"Lawson","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2021.06.003_bib20","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/ijgc-2019-000222","article-title":"Measuring response to neoadjuvant chemotherapy in in high-grade serous tubo-ovarian carcinoma: an analysis of the correlation between CT imaging and chemotherapy response","volume":"29","author":"McNulty","year":"2019","journal-title":"Int J Gynecol Canc"},{"key":"10.1016\/j.humpath.2021.06.003_bib21","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3849","article-title":"Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotype","volume":"49","author":"Wang","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.humpath.2021.06.003_bib22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2021.06.003_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jmoldx.2016.09.011","article-title":"A targeted high-throughput next-generation sequencing panel for clinical screening of mutations, gene amplifications and fusions in solid tumors","volume":"19","author":"Luthra","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2021.06.003_bib24","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1111\/cas.14087","article-title":"Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy","volume":"110","author":"Hatakeyama","year":"2019","journal-title":"Canc Sci"},{"key":"10.1016\/j.humpath.2021.06.003_bib25","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cell.2017.09.048","article-title":"Comprehensive analysis of hypermutation in human cancer","volume":"171","author":"Campbell","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2021.06.003_bib26","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1093\/nar\/gkv111","article-title":"TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer","volume":"43","author":"Chien","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.humpath.2021.06.003_bib27","doi-asserted-by":"crossref","first-page":"15105","DOI":"10.1016\/j.anndiagpath.2020.151505","article-title":"Are polyploid giant cancer cells in high grade serous carcinoma of the ovary blastomere-like cancer stem cells?","volume":"46","author":"Salem","year":"2020","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.humpath.2021.06.003_bib28","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.18632\/oncotarget.27330","article-title":"Avoidance of apoptotic death via a hyperploid salvage survival pathway after platinum treatment in high grade serous carcinoma cell line models","volume":"10","author":"Yeung","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2021.06.003_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2021.06.003_bib30","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1158\/1078-0432.CCR-17-3862","article-title":"Immunogenomic analyses of advanced serous ovarian cancer reveal immune score is a strong prognostic factor and an indicator of chemosensitivity","volume":"24","author":"Hao","year":"2018","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.humpath.2021.06.003_bib31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2021.06.003_bib32","article-title":"Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set","volume":"14","author":"Roszik","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.humpath.2021.06.003_bib33","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.jtho.2019.05.014","article-title":"DNA damage response and repair pathway alteration and its association with tumor mutation burden and platinum-based chemotherapy in SCLC","volume":"14","author":"Park","year":"2019","journal-title":"J Thorac Oncol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817721001106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817721001106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:39:15Z","timestamp":1758645555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817721001106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":33,"alternative-id":["S0046817721001106"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2021.06.003","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TP53 variant allele frequency correlates with the chemotherapy response score in ovarian\/fallopian tube\/peritoneal high-grade serous carcinoma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2021.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}